Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT00327535




Registration number
NCT00327535
Ethics application status
Date submitted
16/05/2006
Date registered
18/05/2006
Date last updated
11/08/2016

Titles & IDs
Public title
A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving First Line Chemotherapy.
Scientific title
A Multicenter, Randomized, Open Label Dose Finding Study of Mircera in Anemic Patients With Stage IIIB or IV Non-small Cell Lung Cancer Receiving First Line Myelosuppressive Chemotherapy
Secondary ID [1] 0 0
NH19960
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Anemia 0 0
Condition category
Condition code
Cancer 0 0 0 0
Lung - Non small cell

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Darbepoetin alfa
Treatment: Drugs - methoxy polyethylene glycol-epoetin beta [Mircera]
Treatment: Drugs - methoxy polyethylene glycol-epoetin beta [Mircera]
Treatment: Drugs - methoxy polyethylene glycol-epoetin beta [Mircera]

Experimental: Mircera 6.3 micrograms/kg -

Experimental: Mircera 9 micrograms/kg -

Experimental: Mircera 12 micrograms/kg -

Active comparator: Darbepoetin alfa -


Treatment: Drugs: Darbepoetin alfa
According to the approved local label (6.75 micrograms/kg every 3 weeks, or 2.25 micrograms/kg every week)

Treatment: Drugs: methoxy polyethylene glycol-epoetin beta [Mircera]
6.3 micrograms/kg every 3 weeks

Treatment: Drugs: methoxy polyethylene glycol-epoetin beta [Mircera]
9 micrograms/kg every 3 weeks

Treatment: Drugs: methoxy polyethylene glycol-epoetin beta [Mircera]
12 micrograms/kg every 3 weeks
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Average Hb change from baseline
Timepoint [1] 0 0
Weeks 5-13
Secondary outcome [1] 0 0
Target Hb therapeutic range, average Hb values, hematopoietic response.
Timepoint [1] 0 0
Days 2-85
Secondary outcome [2] 0 0
Red blood cell (RBC) transfusions
Timepoint [2] 0 0
Weeks 5-13
Secondary outcome [3] 0 0
Adverse events (AEs), laboratory parameters, premature withdrawals
Timepoint [3] 0 0
Throughout study

Eligibility
Key inclusion criteria
* >=18 years of age;
* stage III or IV non-small cell lung cancer receiving first line myelosuppressive chemotherapy;
* myelosuppressive chemotherapy scheduled for at least 9 weeks;
* anemia at screening visit.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* transfusion of red blood cells during the 4 weeks prior to first planned dose of study medication;
* iron deficiency anemia, or anemia caused by gastrointestinal bleeding;
* prior treatment with Mircera.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/05/2006
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/05/2007
Sample size
Target
Accrual to date
Final
153
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
- East Bentleigh
Recruitment hospital [2] 0 0
- Kurralta Park
Recruitment hospital [3] 0 0
- Milton
Recruitment postcode(s) [1] 0 0
VIC 3165 - East Bentleigh
Recruitment postcode(s) [2] 0 0
5037 - Kurralta Park
Recruitment postcode(s) [3] 0 0
4064 - Milton
Recruitment outside Australia
Country [1] 0 0
Austria
State/province [1] 0 0
Linz
Country [2] 0 0
Austria
State/province [2] 0 0
Salzburg
Country [3] 0 0
Austria
State/province [3] 0 0
Wien
Country [4] 0 0
Belgium
State/province [4] 0 0
Aalst
Country [5] 0 0
Belgium
State/province [5] 0 0
Edegem
Country [6] 0 0
Belgium
State/province [6] 0 0
Liege
Country [7] 0 0
Canada
State/province [7] 0 0
Ontario
Country [8] 0 0
Czech Republic
State/province [8] 0 0
Brno
Country [9] 0 0
Czech Republic
State/province [9] 0 0
Hradec Kralove
Country [10] 0 0
Czech Republic
State/province [10] 0 0
Ostrava
Country [11] 0 0
Czech Republic
State/province [11] 0 0
Praha
Country [12] 0 0
Estonia
State/province [12] 0 0
Tallin
Country [13] 0 0
Estonia
State/province [13] 0 0
Tartu
Country [14] 0 0
Finland
State/province [14] 0 0
Helsinki
Country [15] 0 0
France
State/province [15] 0 0
Bobigny
Country [16] 0 0
France
State/province [16] 0 0
Caen
Country [17] 0 0
France
State/province [17] 0 0
Dijon
Country [18] 0 0
France
State/province [18] 0 0
Lyon
Country [19] 0 0
France
State/province [19] 0 0
Paris
Country [20] 0 0
France
State/province [20] 0 0
Pessac
Country [21] 0 0
France
State/province [21] 0 0
Pierre Benite
Country [22] 0 0
France
State/province [22] 0 0
Saint Pierre
Country [23] 0 0
Germany
State/province [23] 0 0
Gauting
Country [24] 0 0
Germany
State/province [24] 0 0
Hamburg
Country [25] 0 0
Germany
State/province [25] 0 0
Heidelberg
Country [26] 0 0
Germany
State/province [26] 0 0
Karlsruhe
Country [27] 0 0
Germany
State/province [27] 0 0
Trier
Country [28] 0 0
Greece
State/province [28] 0 0
Athens
Country [29] 0 0
Greece
State/province [29] 0 0
Heraklion
Country [30] 0 0
Greece
State/province [30] 0 0
Larissa
Country [31] 0 0
Greece
State/province [31] 0 0
Thessaloniki
Country [32] 0 0
Hong Kong
State/province [32] 0 0
Hong Kong
Country [33] 0 0
Hungary
State/province [33] 0 0
Budapest
Country [34] 0 0
Hungary
State/province [34] 0 0
Deszk
Country [35] 0 0
Hungary
State/province [35] 0 0
Mátraháza
Country [36] 0 0
Hungary
State/province [36] 0 0
Nyiregyhaza
Country [37] 0 0
Hungary
State/province [37] 0 0
Szekesfehervar
Country [38] 0 0
Italy
State/province [38] 0 0
Genova
Country [39] 0 0
Italy
State/province [39] 0 0
Legnago
Country [40] 0 0
Italy
State/province [40] 0 0
Novara
Country [41] 0 0
Italy
State/province [41] 0 0
Pavia
Country [42] 0 0
Italy
State/province [42] 0 0
Ravenna
Country [43] 0 0
Italy
State/province [43] 0 0
San Giovanni Rotondo
Country [44] 0 0
Italy
State/province [44] 0 0
Sassari
Country [45] 0 0
Poland
State/province [45] 0 0
Bydgoszcz
Country [46] 0 0
Poland
State/province [46] 0 0
Elblag
Country [47] 0 0
Poland
State/province [47] 0 0
Otwock
Country [48] 0 0
Poland
State/province [48] 0 0
Poznan
Country [49] 0 0
Poland
State/province [49] 0 0
Radom
Country [50] 0 0
Poland
State/province [50] 0 0
Wloclawek
Country [51] 0 0
Poland
State/province [51] 0 0
Wroclaw
Country [52] 0 0
Spain
State/province [52] 0 0
Barcelona
Country [53] 0 0
Spain
State/province [53] 0 0
Girona
Country [54] 0 0
Spain
State/province [54] 0 0
La Laguna
Country [55] 0 0
Spain
State/province [55] 0 0
Madrid
Country [56] 0 0
Spain
State/province [56] 0 0
Zaragoza

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Hoffmann-La Roche
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This 4 arm study will assess the optimal starting dose of Mircera in the treatment of anemia in patients with non-small cell lung cancer receiving first line myelosuppressive chemotherapy. Patients will be randomized to receive either Mircera 6.3 micrograms/kg, 9 micrograms/kg or 12 micrograms/kg s.c. every 3 weeks or darbepoetin alfa according to the approved local label (either 6.75 micrograms/kg s.c. every 3 weeks, or 2.25 micrograms/kg every week). The anticipated time on study treatment is \<3 months and the target sample size is 100-500 individuals.
Trial website
https://clinicaltrials.gov/study/NCT00327535
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Clinical Trials
Address 0 0
Hoffmann-La Roche
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT00327535